Recent News

• 12.11.2025 - Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
• 12.10.2025 - Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
• 11.10.2025 - Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
• 11.07.2025 - Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
• 11.05.2025 - Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
• 11.05.2025 - Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
• 11.04.2025 - Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Recent Filings

• 12.11.2025 - 8-K Current report
• 12.11.2025 - 144 Report of proposed sale of securities
• 12.11.2025 - EX-99.1 EX-99.1
• 11.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.20.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.10.2025 - 144 Report of proposed sale of securities
• 11.07.2025 - 8-K Current report
• 11.07.2025 - 144 Report of proposed sale of securities